No / The interleukin-2-deficient (IL-2¿/¿) mouse model of ulcerative colitis was used to test the hypothesis that colonic epithelial cells (CEC) directly respond to bacterial antigens and that alterations in Toll-like receptor (TLR)-mediated signaling may occur during the development of colitis. TLR expression and activation of TLR-mediated signaling pathways in primary CEC of healthy animals was compared with CEC in IL-2¿/¿ mice during the development of colitis. In healthy animals, CEC expressed functional TLR, and in response to the TLR4 ligand LPS, proliferated and secreted the cytokines IL-6 and monocyte chemoattractant protein-1 (MCP-1). However, the TLR-responsiveness of CEC in IL-2¿/¿ mice was different with decreased TLR4 responsiveness and augmented TLR2 responses that result in IL-6 and MCP-1 secretion. TLR signaling in CEC did not involve NF-B (p65) activation with the inhibitory p50 form of NF-B predominating in CEC in both the healthy and inflamed colon. Development of colitis was, however, associated with the activation of MAPK family members and upregulation of MyD88-independent signaling pathways characterized by increased caspase-1 activity and IL-18 production. These findings identify changes in TLR expression and signaling during the development of colitis that may contribute to changes in the host response to bacterial antigens seen in colitis.

A interleucina-2 (IL-2) atua na modulação da atividade dopaminérgica, que influencia o comportamento maternal. Neste estudo observou-se que o estado lactacional reduziu a atividade geral em campo aberto, porém não alterou os níveis de dopamina e seus metabólitos. A administração de IL-2, tanto sistêmica com diretamente no N.Ac não alterou a atividade geral em campo aberto, indicando a ausência de efeito motor da mesma. Além disso, a administração de IL-2 sistêmica e no N.Ac reduziu as porcentagens de ratas que agrupam os filhotes e de filhotes agrupados por rata. A injeção de IL-2 no N.Ac aumentou as latências de busca do primeiro e segundo filhotes e o comportamento agressivo. A administração sistêmica de IL-2 em ratas virgens reduziu somente do valor absoluto de DOPAC (metabólito de dopamina) após 100 e 120. Este achado corrobora a idéia de que o IL-2 altera a atividade dopaminérgica. Os resultados sugerem que a administração sistêmica da dose de IL-2 estudada não influencia de forma significativa os níveis de dopamina e de seus metabólitos no N.Ac. / Interleukin-2 (IL-2) modulates the dopaminergic neurotransmission, that into the nucleus accumbens (N.Ac) plays a role in maternal behavior. The IL-2 dose used in this study does not have motor effects. Both peripheral and central N.Ac injections decreased the percent of mothers grouping pups together and the number of grouped pups. IL-2 injections into the N.Ac resulted in longer latencies to retrieve first and second pups and increased aggressive behavior. In order to test if these behavioral effects would be related to the IL-2 reduced the DOPAC (dopamine metabolite) concentrations in the N.Ac of virgin rats treated with IL-2. This suggests suggest that the IL-2 dose used in this study does not alter so much the dopaminergic transmission by influencing extracellular levels of this neurotransmitter.

This dissertation addresses the role for Janus Kinase 3 (Jak3) in CD4+ T cell homeostasis and function. Jak3 is a protein tyrosine kinase whose activity is essential for signals mediated by the γc dependent cytokines IL-2, -4, -7, -9, -15, and -21. Previous data have demonstrated that peripheral CD4+ T cells from Jak3-deficient mice have a memory phenotype and are functionally impaired in both proliferative and IL-2 responses in vitro. Interestingly, Jak3/γc activity has been previously shown to play a role in the prevention of T cell anergy. These studies were initiated to more precisely define the role for Jak3/γc cytokines in the prevention of T cell anergy and the maintenance of functional CD4+ T cell responses. We began to address this question by assessing global gene expression changes between wild type and Jak3-/- CD4+ T cells. These data indicate that Jak3-/- CD4+ T cells have an increase in gene expression levels of inhibitory surface receptors as well as immunosuppressive cytokines. Further analyses confirmed that Jak3-deficient T cells express high levels of PD-1, secrete a Trl-type cytokine profile following direct ex vivo activation, and suppress the proliferation of wild type T cells in vitro. These characteristics indicate that CD4+ Jak3-/- T cells share properties with regulatory T cell subsets that have an important role in peripheral tolerance and the prevention of autoimmunity. We next addressed whether these regulatory characteristics were T cell intrinsic or rather the result of expanding in a Jak3-deficient microenvironment characterized by a number of immune abnormalities and a disrupted splenic architecture. Jak3-/- CD4+ T cells proliferate in vivoin a lymphopenic environment and selectively acquire regulatory T cell characteristics in the absence of any additional activation signals. While the precise mechanism by which Jak3-deficient T cells acquire these characteristics remains unclear, our data indicate that one important component is a T cell-intrinsic requirement for Jak3 signaling. These findings indicate several interesting aspects of T cell biology. First, these studies, demonstrate that the homeostatic proliferation of CD4+ T cells is not dependent on signaling via γc-dependent cytokine receptors. And, second, that the weak activation signals normally associated with homeostatic expansion are sufficient to drive Jak3-/- T cells into a non-conventional differentiation program. Previous data indicate that, for wild type T cells, signaling through both the TCR as well as γc-dependent cytokine receptors promote the homeostatic proliferation of T cells in lymphopenic hosts. Since Jak3-/- T cells are unable to receive these cytokine signals, their proliferation is likely to be wholly dependent on TCR signaling. As a consequence of this TCR signaling, Jak3-/- T cells proliferate, but in addition, are induced to up regulate PD-1 and to selectively activate the IL-10 locus while shutting off the production of IL-2. Since this fate does not occur for wild type T cells in a comparable environment, it is likely that the unique differentiation pathway taken by Jak3-/- T cells reflects the effects of TCR signaling in the absence of γc-dependent cytokine signaling. Interestingly, wild type T cells undergoing homeostatic expansion in lymphopenic hosts show many common patterns of gene expression to freshly-purified unmanipulated Jak3-/- T cells. For instance, micro array analysis of gene expression in wild type CD4+ T cells after lymphopenia induced homeostatic expansion show a similar pattern of upregulation in surface markers (PD-1 and LAG-3), and cytokine signaling molecules (IL-10 and IFN-γ cytokine, receptors, and inducible gene targets) to that of Jak3-/- CD4+ T cells immediately ex vivo. These data suggest that the process of homeostatic proliferation normally induces immune attenuation and peripheral tolerance mechanisms, but that full differentiation into a regulatory T cell phenotype is prevented by γc-dependent cytokine signals. Taken together these data suggest that Jak3 plays an important role in tempering typical immune attenuation mechanisms employed to maintain T cell homeostasis and peripheral tolerance.

Chef de file des inhibiteurs de tyrosines kinase, l’Imatinib Mesylate (IM) a révolutionné la prise en charge de la leucémie myéloïde chronique et des tumeurs stromales gastro-intestiales. En plus de son action directe sur les cellules tumorales, une partie de l’efficacité thérapeutique de l’IM a été attribuée à son aptitude à moduler la réponse immunitaire. Cette propriété soulève la possibilité que les résultats cliniques de l’IM pourraient être améliorés en le combinant efficacement à une immunothérapie. A cet effet, nous avons montré dans un modèle préclinique que l’interleukine-2 (IL-2) – adjuvant des cellules NK – augmente l’efficacité de l’IM. Nous avons également démontré une efficacité supérieure de l’IM en association au cyclophosphamide (CTX) du fait de l’inhibition des lymphocytes T régulateurs. Nous avons donc entrepris un essai clinique de phase 1 associant l’IM, l’IL-2 et le CTX chez des patients ayant une tumeur solide métastatique ou localement avancée. Les objectifs de cet essai sont (i) de déterminer la dose maximale tolérée d’IL-2 associée à l’IM et au CTX ; (ii) d’étudier les paramètres pharmacocinétiques de l’association ; (iii) d’évaluer l’efficacité de l’association et (iv) son effet sur les effecteurs de l’immunité. Au total, 17 patients ont été inclus dans cette étude. La DMT d’IL-2 associée à la dose fixe de 400 mg d’IM correspond à 6 MUI/j. A ce niveau de dose, tous les patients ont présenté au moins un effet indésirable imputable au traitement : principalement fièvre et frissons, augmentation des enzymes hépatiques, asthénie et nausée mais sans que ne soit observée de toxicité limitante. L’étude des paramètres pharmacocinétiques révèle une augmentation significative de l’exposition systémique à l’IM en fin de cycle et qui semble être imputable à l’IL-2. La pharmacocinétique de l’IL-2 n’est par contre pas modifiée par l’administration concomitante d’IM. Sur le plan des effecteurs de l’immunité, l’association IM, IL-2 et CTX diminue le taux de lymphocytes B, lymphocytes T (LT) CD4+ et LT CD8+ mais active les cellules NK puisqu’on observe une augmentation des marqueurs CD56bright, HLA-DR et TRAIL. De manière intéressante, la sous-population de cellules NK HLA-DR+ possède des capacités de dégranulation plus importante après exposition à cette association et son expansion est associée à une meilleure survie. Cette association pourrait donc s’avérer particulièrement intéressante dans le traitement de tumeurs sensibles d’une part à l’IM et d’autre part à la lyse par les cellules NK. Les GIST étant particulièrement sensibles à l’IM, nous avons étudié l’infiltrat tumoral présent au niveau de ses tumeurs. Nous avons ainsi pu mettre en évidence le rôle pronostique de l’infiltrat en LT et NK sur la survie sans progression des GIST. En vue d’une étude de phase 2, les GIST apparaissent donc être un modèle tumoral particulièrement pertinent pour évaluer les bénéfices de l’association IM, IL-2 et CTX. / Imatinib mesylate (IM) was the first tyrosine kinase inhibitor to be successfully used in clinical practice and its introduction has revolutionized the management of chronic myeloid leukemia and gastrointestinal stromal tumors. In addition to its direct effects on malignant cells, IM appears to exert immunological off-target effects that contribute to its anticancer effects. Thus, combining IM with immunotherapy might improve patients’ clinical outcome. Indeed, IM combined to Interleukin-2 (IL-2) - a cytokine that enhances natural killer (NK) cells functions - improved antitumor responses in preclinical models. We also observed synergistic effects of cyclophosphamide (CTX) and IM as a result of the inhibition of regulatory T lymphocytes. Based on the promising results of these preclinical studies, we developed a phase 1 clinical trial which combines metronomic CTX, IM and escalating doses of IL-2 in patients affected by refractory solid tumors. The goals of this study were (i) to determine the maximum tolerated dose of IL-2 combined with IM and CTX ; (ii) to study the pharmacokinetics of IM and IL-2 ; (iii) to evaluate clinical efficacy of the combined therapy and (iv) effects of the association on immune parameters. A total of 17 patients were enrolled in the study. The maximum tolerated dose of IL-2 combined with IM, given at a constant dose of 400 mg was determined to be 6 MIU/day. At this dose level, all patients experienced at least one treatment-related adverse event: fevers and chills, transaminase elevation, fatigue and nausea but no dose-limiting toxicities were observed. Pharmacokinetic studies revealed that the co-administration of IL-2 increases the systemic exposure of patients to IM. In contrast, the pharmacokinetics of IL-2 was not modified by IM. The combined therapy markedly reduced the absolute numbers of B lymphocytes, CD4+ T cells and CD8+ T cells in a IL-2 dose-dependant manner. The NK cell compartment was activated, exhibiting a significant upregulation of CD56bright, HLA-DR and TRAIL. Interinstingly, the abundance of HLA-DR+ NK cells after one course of combined therapy positively correlated with both progression free- and overall survival. Thus, it could be of interest to evaluate this immunotherapeutic regimen in a tumor model sensitive to IM and to lysis by NK cells and evaluate whether the adjunction of IL-2 can boost the efficacy of IM. GIST are particularly sensitive to IM, thus we performed a retrospective study of the immune infiltrates and their prognostic value in these tumors. We found that both LT and NK cell infiltrates were independent prognostic factors for progression-free survival. For a phase 2 clinical trial, gastrointestinal stromal tumors appear to be a particularly relevant to evaluate the benefits of the association IM, IL-2 and CTX.

Throughout history, human populations have continuously been challenged by new and emerging infectious diseases. For the past 26 years, sub-Saharan Africa and other countries around the world have been dealing with a pandemic caused by a relatively new pathogen called the human immunodeficiency virus (HIV). Although antiretroviral (ARV) therapies effectively reduce morbidity and mortality rates, the long term use in those who have access to treatment inevitably leads to drug-related toxicity and resistance. Even with a strong commitment from governments to expand and finance prevention and treatment programs, transmission rates continue to outpace the benefits of these efforts. Therefore to effectively eradicate the disease, research is focusing on the design of protective and therapeutic vaccines. The first major step in designing these alternative therapies is to define correlates of immune protection. / The research presented in this thesis focuses on characterizing the quantitative and qualitative features of T cell immune responses in individuals who spontaneously control viral replication and exhibit a benign course of disease while remaining off ARV therapy. A comprehensive analysis of HIV-specific IFN-gamma secreting immune responses revealed that neither the breadth nor the magnitude of responses directed against the entire HIV proteome accurately predicts the viral load or rate of CD4 decline. Subsequent analyses showed that the preferential targeting of Gag was associated with reduced rates of CD4 decline and was later confirmed in a cohort of individuals in primary infection whereby the relative breadth and magnitude of Gag p24 was inversely correlated with viral load set point. / The maintenance of polyfunctional immune responses in HIV-infected subjects with a benign course of disease prompted us to develop a method that could comprehensively assess the breadth, magnitude and specificity of three functionally distinct subsets of HIV-specific lymphocytes (single IFN-gamma, single IL-2 and dual IFN-gamma/IL-2 secretors). Survey of immune responses in chronically infected individuals revealed that only the breadth and magnitude of dual IFN-gamma/IL-2 secreting lymphocytes correlated with reduced viral loads and increased CD4 counts suggesting that secretion of IFN-gamma alone was a poor correlate of protection. We also showed that the contribution of polyfunctional lymphocytes to the total response was greater for epitopes restricted by major histocompatibility complex (MHC) class I alleles associated with slow disease progression compared to those restricted by alleles associated with rapid or neutral rates of HIV disease progression. / Taken together, this work supports the view that immune monitoring of infected and vaccinated individuals should include methodologies capable of detecting both IFN-gamma and IL-2 secretion from responding T lymphocytes. The studies presented here have furthered our understanding of what constitutes protection from disease progression emphasizing that both specificity and polyfunctionality are features of effective control of viral replication.

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 4 uppsatser.

Ulm, Univ., Diss., 2008.

Thesis (Ph. D.)--University of Washington, 2000. / Vita. Includes bibliographical references (leaves 89-102).

A interleucina-2 (IL-2) atua na modulação da atividade dopaminérgica, que influencia o comportamento maternal. Neste estudo observou-se que o estado lactacional reduziu a atividade geral em campo aberto, porém não alterou os níveis de dopamina e seus metabólitos. A administração de IL-2, tanto sistêmica com diretamente no N.Ac não alterou a atividade geral em campo aberto, indicando a ausência de efeito motor da mesma. Além disso, a administração de IL-2 sistêmica e no N.Ac reduziu as porcentagens de ratas que agrupam os filhotes e de filhotes agrupados por rata. A injeção de IL-2 no N.Ac aumentou as latências de busca do primeiro e segundo filhotes e o comportamento agressivo. A administração sistêmica de IL-2 em ratas virgens reduziu somente do valor absoluto de DOPAC (metabólito de dopamina) após 100 e 120. Este achado corrobora a idéia de que o IL-2 altera a atividade dopaminérgica. Os resultados sugerem que a administração sistêmica da dose de IL-2 estudada não influencia de forma significativa os níveis de dopamina e de seus metabólitos no N.Ac. / Interleukin-2 (IL-2) modulates the dopaminergic neurotransmission, that into the nucleus accumbens (N.Ac) plays a role in maternal behavior. The IL-2 dose used in this study does not have motor effects. Both peripheral and central N.Ac injections decreased the percent of mothers grouping pups together and the number of grouped pups. IL-2 injections into the N.Ac resulted in longer latencies to retrieve first and second pups and increased aggressive behavior. In order to test if these behavioral effects would be related to the IL-2 reduced the DOPAC (dopamine metabolite) concentrations in the N.Ac of virgin rats treated with IL-2. This suggests suggest that the IL-2 dose used in this study does not alter so much the dopaminergic transmission by influencing extracellular levels of this neurotransmitter.

Cancer is the second most common cause of death in the world, and the number of people with the disease increases each year. The therapy of the disease currently stands on four pillars; surgery, chemotherapy, radiotherapy, and immunotherapy. Through the past few years, immunotherapy has become the fastest developing treatment modality. However, despite its unprecedented efficacy in some patients, the majority of patients still does not respond to the therapy. Therefore, there is a need to investigate the mechanisms that make immunotherapy inefficient. Cell-based cancer immunotherapy is the treatment modality which uses live ex vivo-produced tumor-targeting immune cells to treat cancer. One of the mechanisms that may compromise its therapeutic efficacy is the expression of inhibitory molecules on the surface of the produced immune cells. Tim-3 is the inhibitory molecule which attracts attention in recent years. Tim-3 expression in the tumor cells and the tumor-infiltrating immune cells is often associated with worse prognosis and more aggressive forms of the disease. However, its role in the in vitro or ex vivo-produced immune cells is difficult to predict. In this work, an in vitro study model which is based on in vitro-produced antigen-specific CD8+ T cells with high expression of Tim-3 has been...